Navigation Links
BioDrain Medical, Inc. Implements Initiatives to Position Itself for Sustained Growth
Date:6/13/2012

MINNEAPOLIS, June 13, 2012 /PRNewswire/ -- BioDrain Medical, Inc. (OTCBB: BIOR, OTCQB: BIOR), producer of the FDA-cleared automated surgical fluid disposal device, the STREAMWAY® System, announced today that under new management it has implemented several initiatives to better position the Company for future growth.

"We are continuing to build an infrastructure that we believe will facilitate and support the rapid sale of STREAMWAY Systems to operating rooms across the U.S.," said Joshua Kornberg, President and Chief Executive Officer of BioDrain. "In particular, we recently enhanced the present design of the STREAMWAY System to increase suction capacity as well as improve overall efficiency. We also established several new relationships with cost-effective manufacturers and distributors to help improve our margins. Moreover, our team is diligently working to create unique marketing programs with additional sales teams and independent contract sales forces throughout the nation."

Helping head BioDrain's sales initiatives is Philip Posa, who was appointed as the Company's Vice President of Sales and Marketing in April 2012, and has over 28 years of experience in the pharmaceutical and diagnostic industry with Abbott Laboratories. BioDrain believes that Mr. Posa's expertise in negotiating contracts with independent sales representative groups and distributors will be invaluable in establishing STREAMWAY Systems in additional hospitals and surgery centers.

"Our goal is to build a best in class national sales force through established independent sales rep groups, several of which we have already started training," said Mr. Posa. "We are also making a concerted effort to gain access to a significant number of hospitals and surgical centers through one or more Group Purchasing Organizations. In providing unlimited surgical fluid disposal capacity, STREAMWAY reduces overhead costs to hospitals and surgical centers, increases compliance rates with the Occupational State and Health Association and other regulatory agencies, and improves efficiency in the operating room. We are confident that we have a superior technology that provides a substantial benefit to our customers."

Further supplementing BioDrain's management team is David Johnson and Bob Myers, whom were recently named the Company's Acting Chief Operating Officer and Chief Financial Officer, respectively. Mr. Johnson has over 35 years of experience in executive, operations and management training positions in rapid growth medical device organizations, directing growth domestically and internationally with products ranging from consumer based disposable commodity items to class III implantable devices. Mr. Myers, formerly a public accountant with the international firm Laventhol & Horwath, has over 30 years of experience in multiple industries focusing on medical device, service and manufacturing.

"As CEO, and a stockholder of BioDrain, I am very mindful of enhancing long-term shareholder value, and I believe that we now have the right people and strategies in place to drive our recurring revenue model and in effect, better reward BioDrain whom stay the course," added Mr. Kornberg. "By restructuring our operations, we are now prepared to support and execute  the sales effort of STREAMWAY Systems on a larger scale. This is a very unique, innovative, patented technology that is easy to install and use, and provides hospitals with substantial safety, efficiency and environmental benefits that we believe will have a significant impact in the industry."

About BioDrain Medical, Inc.
BioDrain Medical, Inc. has a fully automated, patented, FDA-cleared, surgical fluid disposal system that virtually eliminates operating room workers' exposure to blood, irrigation fluid and other potentially infectious fluids found in the surgical environment. Today's manual surgical fluid handling methods of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and an antiquated approach to the handling of surgical fluid waste. BioDrain's STREAMWAY System fully automates the collection, measurement and disposal of surgical fluids resulting in: 1) reducing overhead costs to hospitals and surgical centers, 2) improving the Occupational State and Health Association (OSHA) and other regulatory compliance, and 3) improving the efficiency of the operating room (and thereby making surgeries more profitable).

BioDrain's STREAMWAY System is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease infected canisters go to landfills annually in the United States. These tainted canisters can remain in landfills for years to come. With the installation of BioDrain's STREAMWAY System, the number of canisters can be significantly reduced. BioDrain Medical Inc. makes the operating room and our environment safer, cleaner, and better. BioDrain products are currently being represented by independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers across the country. For additional information, please visit: www.biodrainmedical.com.

Forward-looking Statements:
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See the company's most recent Quarterly Report on Form 10-Q and related 8-K filings.

Investor Contact:

Mr. Kevin Fickle, President
NUWA Group LLC
Tel: +1-925-330-8315            
Email: kevin@nuwagroup.com


'/>"/>
SOURCE BioDrain Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
2. ConvaTec Announces Acquisition of AbViser Medical, LLC
3. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
4. TriReme Medical, Inc. Receives FDA Approval for Glider™ PTCA Catheter
5. Nonin Medical, Inc. Announces U.S. Market Release of EQUANOX™ Advance Model 8004CB Series Sensor for Neonatal, Pediatric Patients
6. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
7. Cook Medical, Zimmer, Pro-Dex & J&J to Share Innovative Social Media Approaches to Marketing Device Products in Minneapolis
8. Comprehensive Care Corporation Implements Steps to Increase Margins and Sustain Profitability
9. Herborium Announces Continuing Progress In Key Strategic Initiatives
10. Uroplasty Announces Product Development and New Clinical Trial Initiatives
11. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016 The life of Dr. ... has been anything but ordinary.  Twists of fate, combined with ... II and the constraints of communist Czechoslovakia to ... would go on to make history by playing a key ... drugs in the world, Remicade.  Dr. Vilcek brings readers along ...
(Date:2/9/2016)... report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - 2019" ... North America continued to lead global anti-bacterial ... into revenues worth US$ 16,907.3 million. North ... , Latin America , Middle-East ... market is inclined towards North America and ...
(Date:2/8/2016)... 2016 Alzheimer Diagnostic Tests - Medical ... Medical Devices sector report , "Alzheimer Diagnostic Tests ... overview of Alzheimer Diagnostic Tests currently in pipeline ... the pipeline products with comparative analysis of the ... reviews major players involved in the pipeline product ...
Breaking Medicine Technology:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... offices in Houma, LA, celebrates the beginning of a new charity campaign. As ... assist Court Appointed Special Advocates (CASA). In the belief that children deserve a ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your clothes are ... alone. According to the Center for Disease Control and Prevention (CDC), 34.9% of U.S. ... certain types of cancer, some of the leading causes of preventable death. February ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic ... of women and men with eating disorders report a history of trauma, research ... development of an eating disorder. , At the 2016 iaedp Symposium, the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Association of ... AHCC and the Home Health and Hospice ICD-10 Transition Workgroup are working closely ... coding guidance and clarifications, to address concerns over the use of 'A' as ...
Breaking Medicine News(10 mins):